Only very limited patients in the triple combo currently, never the less very encouraging data,
efficacy from 10 patients. Early efficacy signals from 10 of 14 patients show ORR of 70% and Disease Control Rate (DCR) of 90% (according to RECIST 1.1), of course noting the very small patient subset evaluated (n=10). It is encouraging at this early stage only 1 of 10 patients have progressive disease.
Overnight Market report, page-1142
Add IMM (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
29.5¢ |
Change
0.005(1.72%) |
Mkt cap ! $428.5M | |||
| Open | High | Low | Value | Volume |
| 28.5¢ | 30.5¢ | 28.5¢ | $469.8K | 1.579M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 9 | 297652 | 29.0¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 30.0¢ | 7500 | 2 |
View Market Depth
| Last trade - 16.10pm 19/07/2024 (20 minute delay) ? |
| IMM (ASX) Chart |